<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257556</url>
  </required_header>
  <id_info>
    <org_study_id>FE999906 CS004 (PROSPECT)</org_study_id>
    <secondary_id>2004-001307-35</secondary_id>
    <nct_id>NCT00257556</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa</brief_title>
  <official_title>A Prospective, Open Label, Randomised, Parallel Group, Comparative Pilot Study to Study the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant FSH (Follitropin Alfa) Administered Subcutaneously to Subfertile Female Patients Undergoing IVF Using Antagonist Downregulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective open label, randomised, parallel group, comparative pilot.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ongoing pregnancy rate, defined as positive fetal heart action 9 weeks after the first
      positive pregnancy test. Number/diameter of follicles, number of oocytes retrieved, number
      of pronuclear oocytes (referred to as zygotes or pre-embryos in the UK), quality of
      pronuclear stage oocytes, number of embryos transferred, quality of embryos, number of
      frozen embryos, endometrial thickness and morphology on day of HCG administration, estradiol
      levels at day of HCG administration, implantation rate, number of days stimulated with
      gonadotrophins and number of ampoules used, clinical pregnancy rate at 6 weeks after the
      first positive pregnancy test, pregnancy outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With an Ongoing Pregnancy</measure>
    <time_frame>Approx week 13; 9 weeks or more after the 1st positive pregnancy test</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Ongoing Pregnancy</measure>
    <time_frame>Approx week 13; 9 weeks or more after the first positive pregnancy test</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Varying Numbers of Follicles That Were Greater Than or Equal to 17 Millimeters</measure>
    <time_frame>Day 7 and, if appropriate, every 2 days thereafter (Days 9/11/13)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Varying Numbers of Oocytes Retrieved</measure>
    <time_frame>Approximately study day 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Varying Numbers of Pronuclear Stage Oocytes</measure>
    <time_frame>Approximately study day 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Varying Numbers of Embryos Transferred</measure>
    <time_frame>Approximately study day 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Varying Numbers of Embryos Frozen</measure>
    <time_frame>Approximately study day 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days Stimulated With Gonadotrophins</measure>
    <time_frame>study days 1 - 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Outcomes</measure>
    <time_frame>Approximately 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Endometrial Thickness</measure>
    <time_frame>Day 7 or 9 or 11 or 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Estradiol Level</measure>
    <time_frame>Day 7 or 9 or 11 or 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Menotrophin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Follitropin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menotrophin</intervention_name>
    <description>150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.</description>
    <arm_group_label>Menotrophin</arm_group_label>
    <other_name>Menopur</other_name>
    <other_name>hMG</other_name>
    <other_name>highly purified menotrophin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa</intervention_name>
    <description>150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.</description>
    <arm_group_label>Follitropin alfa</arm_group_label>
    <other_name>rFSH</other_name>
    <other_name>recombinant FSH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Female patients aged &gt; or = 20 and &lt; or = 35 years with a BMI of &gt;18 and &lt;32 kg/m2 who
        have received no more than two previous cycles of in vitro fertilisation (IVF) or other
        assisted reproductive technique (ART) and whose partners have normal sperm (according to
        WHO 1999 criteria).

        Inclusion criteria:

          -  Signed informed consent;

          -  Subfertile premenopausal female patients eligible for IVF treatment;

          -  Aged &gt;=20 and &lt;=35 years;

          -  Body mass index of &gt;18 and &lt;32 kg/m2

          -  Normal endocrine assessment within the last 6 months;

          -  Normal pelvic ultrasound (showing two ovaries, no ovarian abnormalities and normal
             uterus) within the last 6 months;

          -  Receipt of no more than two previous cycles of IVF (or other ART);

          -  At least 3 consecutive ovulatory menstrual cycles of 24-35 days, and documented
             evidence of ovulatory cycles within the previous 12 months;

          -  No fertility-modifying treatment within the 3 months prior to this treatment cycle;

          -  Infertility attributable to or in association with either tubal factor, or
             unexplained causes;

          -  Sperm of partner classed as normal according to WHO 1999 criteria within the year
             prior to beginning therapy;

          -  Negative serum beta-HCG pregnancy test prior to beginning therapy;

          -  Clinically normal baseline haematology, clinical chemistry, and urinalysis parameter
             values, negative serum HBsAg and HIV antibody tests;

          -  Screening endocrine test results (estradiol, LH, FSH, progesterone, prolactin, TSH)
             in early follicular phase within the normal limits for the clinical laboratory.

        Exclusion criteria

          -  Presence of any clinically relevant systemic disease(e.g. insulin- dependent diabetes
             mellitus);

          -  A history of or current endocrine disease, including polycystic ovary- like syndrome
             and hyperprolactinaemia;

          -  A history of coagulation disorders;

          -  Persistent ovarian cysts;

          -  Contraindications for the use of gonadotrophins or GnRH antagonists;

          -  A history of hypersensitivity to any of the constituents of the study medication or
             related compounds;

          -  Three or more previous cycles of IVF (or other ART);

          -  A history of alcohol abuse (more than 30 units per week on a regular basis);

          -  History of chemo- or radiotherapy;

          -  Currently breast-feeding, pregnant or with a contraindication to pregnancy;

          -  Diagnosed poor responders in prior IVF treatment;

          -  History of severe ovarian hyperstimulation syndrome (OHSS) (4 or 5) in former IVF
             treatment;

          -  Investigational drug within the 30 days prior to treatment;

          -  Any other condition or history that the investigator considers might increase the
             risk to the individual.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis und Tagesklinik, Olpe 19</name>
      <address>
        <city>Dortmund</city>
        <zip>44135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Frauenklinik Heidelberg Abt. Gynakologische Endokrinologie und Fertilitatsstorungen, Voßstr. 9</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis und Tagesklinik, Zingel 29</name>
      <address>
        <city>Hildesheim</city>
        <zip>1134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh, 51 Little France</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary, Great George Street</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Hallamshire Hospital, University of Sheffield, Jessop Wing, Tree Root Walk</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>February 12, 2010</lastchanged_date>
  <firstreceived_date>November 22, 2005</firstreceived_date>
  <firstreceived_results_date>January 8, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Clinical Development Support</name_title>
    <organization>Ferring Pharmaceuticals</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Ninety (90) participants were screened and 80 participants randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Menotrophin</title>
          <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
        </group>
        <group group_id="P2">
          <title>Follitropin Alfa</title>
          <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Patients Treated Population</title>
              <participants_list>
                <participants group_id="P1" count="37">Also the safety population. One randomized patient did not receive study medication.</participants>
                <participants group_id="P2" count="39">Also the safety population. Three randomized patients did not receive study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet hCG criterion</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Menotrophin</title>
          <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
        </group>
        <group group_id="B2">
          <title>Follitropin Alfa</title>
          <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30.7" spread="3.45"/>
                <measurement group_id="B2" value="30.9" spread="2.67"/>
                <measurement group_id="B3" value="30.8" spread="3.06"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Tobacco Use</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Smoker</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ex-smoker</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Never Smoked</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index (BMI) is measure of body fat based on height and weight that applies to both adult men and women</description>
          <units>Kilograms/Meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.02" spread="3.689"/>
                <measurement group_id="B2" value="23.81" spread="3.731"/>
                <measurement group_id="B3" value="23.91" spread="3.687"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="74.1" spread="8.83"/>
                <measurement group_id="B2" value="73.8" spread="9.96"/>
                <measurement group_id="B3" value="74.0" spread="9.37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Pulse</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="75.7" spread="9.63"/>
                <measurement group_id="B2" value="74.5" spread="9.16"/>
                <measurement group_id="B3" value="75.1" spread="9.35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="115.3" spread="12.50"/>
                <measurement group_id="B2" value="116.1" spread="14.55"/>
                <measurement group_id="B3" value="115.7" spread="13.51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Ongoing Pregnancy</title>
        <description>Number of participants who met human chorionic gonadotrophin (hCG) criterion, received an embryo transfer, tested positive with a serum pregnancy test 11-14 days after embryo transfer and had an ongoing pregnancy (defined as positive fetal heart action) at ≥ 9 weeks after the first positive pregnancy test.</description>
        <time_frame>Approx week 13; 9 weeks or more after the 1st positive pregnancy test</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With an Ongoing Pregnancy</title>
            <description>Number of participants who met human chorionic gonadotrophin (hCG) criterion, received an embryo transfer, tested positive with a serum pregnancy test 11-14 days after embryo transfer and had an ongoing pregnancy (defined as positive fetal heart action) at ≥ 9 weeks after the first positive pregnancy test.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Ongoing Pregnancy</title>
        <description>Percentage of participants who had an ongoing pregnancy ≥ 9 weeks after the first positive pregnancy test, as indicated by positive fetal heart action.</description>
        <time_frame>Approx week 13; 9 weeks or more after the first positive pregnancy test</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population. Two menotrophin patients did not have pregnancy outcome data recorded in this timeframe but were later recorded as having live births so are included here as &quot;YES&quot; for ongoing pregnancy.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With an Ongoing Pregnancy</title>
            <description>Percentage of participants who had an ongoing pregnancy ≥ 9 weeks after the first positive pregnancy test, as indicated by positive fetal heart action.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.8"/>
                  <measurement group_id="O2" value="33.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.170</ci_lower_limit>
            <ci_upper_limit>0.260</ci_upper_limit>
            <estimate_desc>A two-sided 95% continuity-corrected confidence interval for the difference in percentages, based on the normal approximation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Varying Numbers of Follicles That Were Greater Than or Equal to 17 Millimeters</title>
        <description>The criterion for ovulation induction was three follicles ≥ 17 mm diameter as shown by pelvic ultrasound examination. Patients were assessed by pelvic ultrasound on the morning (prior to menotrophin or follitropin alfa administration) of Day 7 and, if appropriate, every 2 days thereafter (Days 9/11/13) until the criterion was met.</description>
        <time_frame>Day 7 and, if appropriate, every 2 days thereafter (Days 9/11/13)</time_frame>
        <safety_issue>No</safety_issue>
        <population>All treated patients population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varying Numbers of Follicles That Were Greater Than or Equal to 17 Millimeters</title>
            <description>The criterion for ovulation induction was three follicles ≥ 17 mm diameter as shown by pelvic ultrasound examination. Patients were assessed by pelvic ultrasound on the morning (prior to menotrophin or follitropin alfa administration) of Day 7 and, if appropriate, every 2 days thereafter (Days 9/11/13) until the criterion was met.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Did not meet criterion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>7 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11-14 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>16 follicles ≥ 17 mm in diameter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Varying Numbers of Oocytes Retrieved</title>
        <description>Number of participants with grouped by the number of oocytes retrieved. Oocytes were retrieved following ovulation induction by subcutaneous administration of human chorionic gonadotrophin (hCG) in the form of choriogonadotropin alfa at a dose of 250 micrograms once participants reached the criteria of at least three follicles with &gt;= 17mm in diameter.</description>
        <time_frame>Approximately study day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All treated patients population.</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varying Numbers of Oocytes Retrieved</title>
            <description>Number of participants with grouped by the number of oocytes retrieved. Oocytes were retrieved following ovulation induction by subcutaneous administration of human chorionic gonadotrophin (hCG) in the form of choriogonadotropin alfa at a dose of 250 micrograms once participants reached the criteria of at least three follicles with &gt;= 17mm in diameter.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>0 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 oocyte retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>7 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>13 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>14 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>16 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>17-18 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>19 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>20 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>21 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>22 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>23 oocytes retrieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Varying Numbers of Pronuclear Stage Oocytes</title>
        <description>Number of participants with various groupings of pronuclear oocytes retrieved 16-20 hours after insemination.</description>
        <time_frame>Approximately study day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varying Numbers of Pronuclear Stage Oocytes</title>
            <description>Number of participants with various groupings of pronuclear oocytes retrieved 16-20 hours after insemination.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>1 pronuclear stage oocyte</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>7 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>13 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>14-16 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>17 pronuclear stage oocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Varying Numbers of Embryos Transferred</title>
        <description>Number of participants with various categories of numbers of embryos transferred.</description>
        <time_frame>Approximately study day 17</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varying Numbers of Embryos Transferred</title>
            <description>Number of participants with various categories of numbers of embryos transferred.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>0 embryos transferred</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 embryo transferred</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 embryos transferred</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 embryos transferred</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Varying Numbers of Embryos Frozen</title>
        <description>Number of participants with different categories of number of embryos frozen.</description>
        <time_frame>Approximately study day 17</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varying Numbers of Embryos Frozen</title>
            <description>Number of participants with different categories of number of embryos frozen.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>0 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 embryo frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6-8 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 embryos frozen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days Stimulated With Gonadotrophins</title>
        <description>Number of days stimulated with study drug until participant met the criteria for ovulation induction. Ovulation induction criteria is three follicles greater than or equal to 17 mm diameter as shown by pelvic ultrasound examination.</description>
        <time_frame>study days 1 - 13</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Number of Days Stimulated With Gonadotrophins</title>
            <description>Number of days stimulated with study drug until participant met the criteria for ovulation induction. Ovulation induction criteria is three follicles greater than or equal to 17 mm diameter as shown by pelvic ultrasound examination.</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.2" spread="1.71"/>
                  <measurement group_id="O2" value="8.9" spread="1.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Outcomes</title>
        <description>Long term follow-up to determine the outcome of the pregnancy.</description>
        <time_frame>Approximately 10 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pregnancy Outcomes</title>
            <description>Long term follow-up to determine the outcome of the pregnancy.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Miscarriage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pre-term: 1 live birth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pre-term: 2 live births</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pre-term stillbirth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Full term: 1 live birth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Full term: 2 live births</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Endometrial Thickness</title>
        <description>Measurement performed on day of human chorionic gonadotrophin (hCG) administration/ovulation induction.</description>
        <time_frame>Day 7 or 9 or 11 or 13</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Endometrial Thickness</title>
            <description>Measurement performed on day of human chorionic gonadotrophin (hCG) administration/ovulation induction.</description>
            <units>millimeters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.7" spread="2.73"/>
                  <measurement group_id="O2" value="11.0" spread="2.31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Estradiol Level</title>
        <description>Measurement on day of human chorionic gonadotrophin (hCG) administration / ovulation induction.</description>
        <time_frame>Day 7 or 9 or 11 or 13</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patient treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Menotrophin</title>
            <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Alfa</title>
            <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Estradiol Level</title>
            <description>Measurement on day of human chorionic gonadotrophin (hCG) administration / ovulation induction.</description>
            <units>picomoles / liter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6706.6" spread="4109.26"/>
                  <measurement group_id="O2" value="6268.3" spread="4132.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The 'all patients treated' population is the same as the safety population in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Menotrophin</title>
          <description>Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)</description>
        </group>
        <group group_id="E2">
          <title>Follitropin Alfa</title>
          <description>A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abortion Imminent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Hyperstimulation Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ovarian Hyperstimulation Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restiction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
